Bliss GVS Pharma Ltd

₹ 234 2.08%

02 Apr - close price

About

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Key Points

Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. ^[1] ^[2]

Website BSE NSE

Market Cap ₹ 2,477 Cr.
Current Price ₹ 234
High / Low ₹ 244 / 105
Stock P/E 22.4
Book Value ₹ 107
Dividend Yield 0.21 %
ROCE 11.7 %
ROE 8.36 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.

Cons

The company has delivered a poor sales growth of 3.27% over past five years.
Company has a low return on equity of 8.95% over last 3 years.
Earnings include an other income of Rs.71.9 Cr.
Company has high debtors of 198 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE Allcap

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	206	185	160	212	201	198	184	218	210	198	207	244	218
	158	179	135	158	157	170	149	176	181	177	166	201	183
Operating Profit	48	6	24	54	44	28	34	41	30	21	41	43	35
OPM %	23%	3%	15%	26%	22%	14%	19%	19%	14%	11%	20%	18%	16%
	6	3	5	13	5	-24	4	5	15	12	35	8	16
Interest	1	5	1	1	2	2	2	4	1	2	5	3	1
Depreciation	5	5	6	6	7	7	7	7	8	8	8	8	8
Profit before tax	47	-1	22	59	40	-4	30	36	36	23	63	41	41
Tax %	37%	-561%	34%	27%	27%	24%	26%	28%	29%	29%	30%	30%	39%
	30	3	14	43	29	-5	22	26	26	17	44	29	25
EPS in Rs	2.68	0.32	1.41	4.05	2.64	-0.87	1.97	2.31	2.26	1.47	4.08	2.58	2.20
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	345	407	547	798	815	899	689	577	747	752	770	810	868
	273	304	391	596	618	739	566	471	629	634	620	683	727
Operating Profit	71	103	156	203	197	160	123	107	118	117	151	127	141
OPM %	21%	25%	29%	25%	24%	18%	18%	18%	16%	16%	20%	16%	16%
	28	20	24	12	-8	35	26	20	-42	18	-0	36	72
Interest	18	16	19	20	23	4	8	6	5	10	7	8	12
Depreciation	11	11	13	20	21	9	13	17	17	19	26	29	33
Profit before tax	71	96	148	175	145	182	129	104	54	106	117	126	168
Tax %	42%	36%	32%	36%	39%	30%	26%	29%	57%	28%	30%	28%
	41	61	100	113	89	127	95	74	23	77	82	90	114
EPS in Rs	3.97	5.81	8.00	7.95	5.70	11.99	9.43	6.64	1.45	6.80	7.21	8.00	10.33
Dividend Payout %	13%	12%	6%	8%	18%	8%	5%	8%	34%	7%	7%	6%

Compounded Sales Growth
10 Years:	7%
5 Years:	3%
3 Years:	3%
TTM:	7%

Compounded Profit Growth
10 Years:	3%
5 Years:	-5%
3 Years:	44%
TTM:	38%

Stock Price CAGR
10 Years:	6%
5 Years:	18%
3 Years:	47%
1 Year:	95%

Return on Equity
10 Years:	12%
5 Years:	8%
3 Years:	9%
Last Year:	8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	10	10	10	10	10	10	10	10	10	10	10	11	11
Reserves	277	327	402	476	526	636	725	798	808	873	957	1,040	1,122
	173	160	132	225	118	102	126	122	109	102	100	88	52
	123	166	218	311	206	157	168	147	181	171	145	162	215
Total Liabilities	583	662	762	1,023	860	905	1,030	1,077	1,109	1,157	1,212	1,301	1,400
	213	234	225	305	143	146	242	234	281	379	370	406	392
CWIP	4	0	9	4	0	47	0	2	22	3	8	21	39
Investments	0	0	0	0	0	0	0	0	2	8	4	4	10
	365	428	527	714	717	712	788	840	803	768	830	870	959
Total Assets	583	662	762	1,023	860	905	1,030	1,077	1,109	1,157	1,212	1,301	1,400

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	41	38	113	289	18	40	47	64	135	34	103	106
	-11	-29	-50	-249	48	-79	-40	-45	-103	-6	-83	-75
	-8	-42	-40	-10	-76	17	-6	-21	-24	-25	-21	-30
Net Cash Flow	22	-34	23	30	-10	-22	0	-2	9	3	-1	0
Free Cash Flow	25	5	101	186	-7	2	-12	55	63	-59	75	33
CFO/OP	106%	45%	101%	160%	29%	-8%	69%	87%	143%	67%	91%	113%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	228	222	201	116	134	187	290	293	192	187	192	198
Inventory Days	70	69	55	50	55	46	64	110	116	94	113	111
Days Payable	176	165	153	100	55	47	75	82	86	79	58	63
Cash Conversion Cycle	121	126	102	67	134	186	279	321	221	202	247	246
Working Capital Days	86	105	84	-10	135	154	232	264	179	192	207	199
ROCE %	20%	23%	31%	29%	27%	26%	18%	12%	14%	12%	14%	12%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Global Market Presence (Countries)
Number

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
xx		xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
		xxx		xxx	xxx	xxx		xxx	xxx	xxx
		x,xxx		xxx	xxx	x,xxx		x,xxx	xxx	xxx
				x	x		x	x	x	x
								xx	xx	xx
									xx	xx
				x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Number of Branded Formulations/SKUs
Number

Total Employees
Number

Suppositories & Pessaries Capacity (Unit 2 & 3)
Million Units ・Standalone data

Tablets Capacity (Palghar Unit 1)
Million Units ・Standalone data

Total Manufacturing Units
Number

Dealer/Distributor Count
Number

Revenue Concentration - African Region
%

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Shareholding Pattern

Numbers in percentages

81 Recently

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	35.04%	35.12%	35.06%	34.97%	34.97%	34.90%	34.82%	35.10%	35.29%	35.44%	35.39%	35.36%
	16.60%	16.50%	16.31%	15.35%	14.74%	13.24%	12.13%	13.51%	13.18%	12.65%	13.27%	14.54%
	6.63%	6.62%	6.61%	6.60%	6.59%	6.58%	6.56%	6.55%	6.55%	6.54%	5.98%	5.78%
	41.73%	41.73%	42.00%	43.08%	43.71%	45.27%	46.49%	44.84%	44.98%	45.37%	45.36%	44.32%
No. of Shareholders	43,041	42,182	43,234	40,758	45,157	44,737	52,937	49,558	49,517	46,707	44,461	43,380

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Dec 2025
	60.16%	60.16%	41.60%	41.60%	33.31%	33.14%	35.04%	34.97%	35.29%	35.36%
	5.44%	10.84%	23.87%	24.16%	22.83%	17.33%	16.60%	14.74%	13.18%	14.54%
	0.25%	0.14%	1.62%	2.96%	6.72%	6.66%	6.63%	6.59%	6.55%	5.78%
	34.15%	28.86%	32.91%	31.28%	37.14%	42.87%	41.73%	43.71%	44.98%	44.32%
No. of Shareholders	15,811	19,930	15,010	14,151	28,543	45,866	43,041	45,157	49,517	43,380

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Aug 2019

Transcript

AI Summary
PPT
May 2019

Transcript

AI Summary
PPT
Feb 2019

Transcript

AI Summary
PPT
Nov 2018

Transcript

AI Summary
PPT
Aug 2018

Transcript

AI Summary
PPT
May 2018

Transcript

AI Summary
PPT
Jan 2018

Transcript

AI Summary
PPT